{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:32:37Z","timestamp":1792096357913,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.coi.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T23:32:50Z","timestamp":1555457570000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"special_numbering":"C","title":["Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine"],"prefix":"10.1016","volume":"59","author":[{"given":"Thomas C","family":"Heineman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2019.02.009_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"J R Soc Med"},{"key":"10.1016\/j.coi.2019.02.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.coi.2019.02.009_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0020","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.009_bib0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0030","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults \u226550 years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2019.02.009_bib0035","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.vaccine.2011.04.019","article-title":"Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection","volume":"29","author":"Oxman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2019.02.009_sbref0040","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0050","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0055","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0060","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2019.02.009_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.mi.44.100190.000423","article-title":"Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking","volume":"44","author":"Grose","year":"1990","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.coi.2019.02.009_bib0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(05)70312-3","article-title":"Immune responses to varicella-zoster virus","volume":"10","author":"Arvin","year":"1996","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.coi.2019.02.009_bib0075","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2019.02.009_bib0080","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2019.02.009_bib0085","doi-asserted-by":"crossref","first-page":"39475","DOI":"10.1038\/srep39475","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2019.02.009_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coi.2019.02.009_sbref0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2019.02.009_bib0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2019.02.009_bib0105","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.009_sbref0110","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.02.009_bib0115","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_sbref0120","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2019.02.009_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2019.02.009_bib0130","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0135","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coi.2019.02.009_bib0140","doi-asserted-by":"crossref","first-page":"e1006083","DOI":"10.1371\/journal.ppat.1006083","article-title":"Role of occult and post-acute phase replication in protective immunity induced with a novel live attenuated SIV vaccine","volume":"12","author":"Berry","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2019.02.009_bib0145","doi-asserted-by":"crossref","first-page":"e91438","DOI":"10.1172\/jci.insight.91438","article-title":"Twelve-year survival and immune correlates in dendritic cell\u2013vaccinated melanoma patients","volume":"2","author":"Gross","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2019.02.009_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.01793-16","article-title":"Human asymptomatic epitopes identified from the herpes simplex virus tegument protein VP13\/14 (UL47) preferentially recall polyfunctional effector memory CD44high CD62Llow CD8+ TEM cells and protect humanized HLA-A*02:01 transgenic mice against ocular","volume":"91","author":"Srivastava","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2019.02.009_bib0155","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coi.2019.02.009_bib0160","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ofid\/ofy209.019","article-title":"Immunogenicity, safety, and post-hoc efficacy assessment of the adjuvanted recombinant zoster vaccine in adults with hematologic malignancies: a phase 3, randomized clinical trial","volume":"5","author":"Dagnew","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0165","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0170","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/ofid\/ofy210.2136","article-title":"Twelve-month immunogenicity and safety of an adjuvanted recombinant zoster vaccine in immunosuppressed adults post renal transplant: a phase III randomized clinical trial","volume":"5","author":"Vink","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0175","first-page":"S417","article-title":"Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II\/III, randomized clinical trial","volume":"4","author":"Vink","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coi.2019.02.009_bib0180","first-page":"S417","article-title":"Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine (HZ\/su) in adults post renal transplant: a phase III randomized clinical trial","volume":"4","author":"Vink","year":"2017","journal-title":"Open Forum Infect Dis"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791518301705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791518301705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:35:08Z","timestamp":1760603708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791518301705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"alternative-id":["S0952791518301705"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2019.02.009","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}